The Alzheimer's research controversies exposed serious problems with the amyloid theory and highlighted the need for a Precision Medicine approach that investigates the underlying causes of cognitive decline.
Why do some patients with MCI or Alzheimer’s improve while others decline? Learn how root causes, genetics, neuroplasticity, and protocol compliance affect outcomes.
Heavy metals and environmental toxins may contribute to brain fog, memory loss, Mild Cognitive Impairment, and Alzheimer's disease. Learn how Precision Medicine investigates toxic exposures and supports brain health.
Mold exposure may contribute to brain fog, memory loss, Mild Cognitive Impairment, and Alzheimer's disease. Learn how mold-related inflammation and toxins may affect brain health and why a Precision Medicine approach matters.
Chronic inflammation may be one of the biggest drivers of memory loss, Mild Cognitive Impairment, and Alzheimer's disease. Learn why inflammation matters and how a Precision Medicine approach addresses root causes.
APOE4 is a genetic risk factor for Alzheimer’s disease, but it’s not a diagnosis or a life sentence. Many people with APOE4 never develop cognitive decline, while others without it may. Understanding APOE4 is about more than just genetics; it’s about how biology interacts with lifestyle, inflammation, and environment. Instead of succumbing to fear, we should focus on personalized strategies for brain health. At the Carroll Institute, we believe in a proactive approach that empowers individuals to take charge of their cognitive health. Discover how you can use this information to protect and support your brain.
Emerging research, including the EVANTHEA Precision Medicine Study, suggests that cognitive decline may not always be a one-way street. In the EVANTHEA study, participants demonstrated improvements in cognitive measures over the course of the study rather than simply experiencing a slower rate of decline
At the Carroll Institute, we believe that cognitive decline is often influenced by multiple biological and neurological factors occurring simultaneously. These may include inflammation, insulin resistance, sleep disorders, vascular dysfunction, hormonal imbalances, nutritional deficiencies, environmental toxins, and changes in brain network function. The diagnosis tells us there is a problem. The real work begins when we identify what is causing it.
Is Alzheimer’s disease simply a drug deficiency, or does it reflect a systems breakdown in the brain? For decades, research focused on finding a single molecule to target, but results have fallen short. At The Carroll Institute, we believe that understanding the interconnected systems of metabolism, inflammation, sleep, and more is crucial. When multiple systems struggle, cognitive decline can occur. This comprehensive approach offers hope for patients and families, revealing that there may be many opportunities for intervention. Discover how a systems-based evaluation can change the conversation around Alzheimer’s disease and cognitive health.
Drugs like lecanemab and donanemab successfully remove amyloid from the brain, yet they do not restore lost memory or reverse Alzheimer's disease. Patients generally continue to decline, although at a somewhat slower rate. That raises an important question: If amyloid is truly the primary cause of Alzheimer's disease, why doesn't removing it produce dramatically greater improvement? At the Carroll Institute, we believe amyloid may be part of the story, but not the whole story. The brain is influenced by inflammation, metabolism, sleep, hormones, toxins, vascular health, and neural network function.
